Photodynamic therapy for lung cancers based on novel photodynamic diagnosis using talaporfin sodium (NPe6) and autofluorescence bronchoscopy

Lung Cancer ◽  
2007 ◽  
Vol 58 (3) ◽  
pp. 317-323 ◽  
Author(s):  
Jitsuo Usuda ◽  
Hidemitsu Tsutsui ◽  
Hidetoshi Honda ◽  
Shuji Ichinose ◽  
Taichirou Ishizumi ◽  
...  
Keyword(s):  
Photodynamic Therapy ◽  
Photodynamic Diagnosis ◽  
Lung Cancers ◽  
Talaporfin Sodium ◽  
Autofluorescence Bronchoscopy

scholarly journals Our Experience With Photodynamic Diagnosis and Photodynamic Therapy for Lung Cancer

2012 ◽  
Vol 10 (Suppl_2) ◽  
pp. S-3-S-8 ◽  
Author(s):  
Harubumi Kato
Keyword(s):  
Lung Cancer ◽  
Optical Coherence Tomography ◽  
Photodynamic Therapy ◽  
Early Stage ◽  
Lung Tumors ◽  
Photodynamic Diagnosis ◽  
Light Sources ◽  
Fiberoptic Bronchoscope ◽  
Lung Cancers ◽  
Diagnosis Of Lung Cancer

The diagnosis of lung cancer was significantly enhanced by the development of the fiberoptic bronchoscope in 1965. Since then, advances in photosensitizers and light sources have brought photodynamic medicine into the light. This article offers an historic overview of the emergence of photodynamic medicine through the perspective of a pioneer with more than 30 years’ experience. Along with a discussion of photodynamic diagnosis of lung cancers via optical coherence tomography, the curative, palliative, and neoadjuvant roles of photodynamic therapy for early and advanced lung cancers are explored. An emerging strategy of using PDM to treat peripheral early-stage lung tumors is briefly discussed.

scholarly journals Systematic Review and Meta-Analysis of In Vitro Anti-Human Cancer Experiments Investigating the Use of 5-Aminolevulinic Acid (5-ALA) for Photodynamic Therapy

2021 ◽  
Vol 14 (3) ◽  
pp. 229
Author(s):  
Yo Shinoda ◽  
Daitetsu Kato ◽  
Ryosuke Ando ◽  
Hikaru Endo ◽  
Tsutomu Takahashi ◽  
...  
Keyword(s):  
Systematic Review ◽  
Photodynamic Therapy ◽  
Aminolevulinic Acid ◽  
Human Cancer ◽  
Meta Analysis ◽  
Protoporphyrin Ix ◽  
Cell Types ◽  
Amino Acid Derivative ◽  
Photodynamic Diagnosis

5-Aminolevulinic acid (5-ALA) is an amino acid derivative and a precursor of protoporphyrin IX (PpIX). The photophysical feature of PpIX is clinically used in photodynamic diagnosis (PDD) and photodynamic therapy (PDT). These clinical applications are potentially based on in vitro cell culture experiments. Thus, conducting a systematic review and meta-analysis of in vitro 5-ALA PDT experiments is meaningful and may provide opportunities to consider future perspectives in this field. We conducted a systematic literature search in PubMed to summarize the in vitro 5-ALA PDT experiments and calculated the effectiveness of 5-ALA PDT for several cancer cell types. In total, 412 articles were identified, and 77 were extracted based on our inclusion criteria. The calculated effectiveness of 5-ALA PDT was statistically analyzed, which revealed a tendency of cancer-classification-dependent sensitivity to 5-ALA PDT, and stomach cancer was significantly more sensitive to 5-ALA PDT compared with cancers of different origins. Based on our analysis, we suggest a standardized in vitro experimental protocol for 5-ALA PDT.

Evaluation of the efficacy and safety of salvage photodynamic therapy by talaporfin sodium for cervical esophageal cancers and lesions larger than 3 cm

Esophagus ◽  
2020 ◽  
Author(s):  
Tomoyuki Hayashi ◽  
Yoshiro Asahina ◽  
Hiroyoshi Nakanishi ◽  
Takeshi Terashima ◽  
Koichi Okamoto ◽  
...  
Keyword(s):  
Photodynamic Therapy ◽  
Efficacy And Safety ◽  
Talaporfin Sodium ◽  
Esophageal Cancers

scholarly journals Preclinical Validation of Talaporfin Sodium-Mediated Photodynamic Therapy for Esophageal Squamous Cell Carcinoma

PLoS ONE ◽  
2014 ◽  
Vol 9 (8) ◽  
pp. e103126 ◽  
Author(s):  
Shinya Ohashi ◽  
Osamu Kikuchi ◽  
Mihoko Tsurumaki ◽  
Yukie Nakai ◽  
Hiroi Kasai ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Photodynamic Therapy ◽  
Esophageal Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Talaporfin Sodium

Advantages of salvage photodynamic therapy using talaporfin sodium for local failure after chemoradiotherapy or radiotherapy for esophageal cancer

2019 ◽  
Vol 34 (2) ◽  
pp. 899-906 ◽  
Author(s):  
Tatsunori Minamide ◽  
Yusuke Yoda ◽  
Keisuke Hori ◽  
Kensuke Shinmura ◽  
Yasuhiro Oono ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Photodynamic Therapy ◽  
Local Failure ◽  
Talaporfin Sodium

scholarly journals Enhanced Malignant Phenotypes of Glioblastoma Cells Surviving NPe6-Mediated Photodynamic Therapy are Regulated via ERK1/2 Activation

Cancers ◽  
2020 ◽  
Vol 12 (12) ◽  
pp. 3641
Author(s):  
Tatsuya Kobayashi ◽  
Makoto Miyazaki ◽  
Nobuyoshi Sasaki ◽  
Shun Yamamuro ◽  
Eita Uchida ◽  
...  
Keyword(s):  
Cell Death ◽  
Photodynamic Therapy ◽  
Migration And Invasion ◽  
Dependent Manner ◽  
Potential Therapeutic Target ◽  
Talaporfin Sodium ◽  
Polymerase Inhibitor ◽  
Human Gbm ◽  
Dose Dependent

To manage refractory and invasive glioblastomas (GBM)s, photodynamic therapy (PDT) using talaporfin sodium (NPe6) (NPe6-PDT) was recently approved in clinical practice. However, the molecular machineries regulating resistance against NPe6-PDT in GBMs and mechanisms underlying the changes in GBM phenotypes following NPe6-PDT remain unknown. Herein, we established an in vitro NPe6-mediated PDT model using human GBM cell lines. NPe6-PDT induced GBM cell death in a NPe6 dose-dependent manner. However, this NPe6-PDT-induced GBM cell death was not completely blocked by the pan-caspase inhibitor, suggesting NPe6-PDT induces both caspase-dependent and -independent cell death. Moreover, treatment with poly (ADP-ribose) polymerase inhibitor blocked NPe6-PDT-triggered caspase-independent GBM cell death. Next, it was also revealed resistance to re-NPe6-PDT of GBM cells and GBM stem cells survived following NPe6-PDT (NPe6-PDT-R cells), as well as migration and invasion of NPe6-PDT-R cells were enhanced. Immunoblotting of NPe6-PDT-R cells to assess the behavior of the proteins that are known to be stress-induced revealed that only ERK1/2 activation exhibited the same trend as migration. Importantly, treatment with the MEK1/2 inhibitor trametinib reversed resistance against re-NPe6-PDT and suppressed the enhanced migration and invasion of NPe6-PDT-R cells. Overall, enhanced ERK1/2 activation is suggested as a key regulator of elevated malignant phenotypes of GBM cells surviving NPe6-PDT and is therefore considered as a potential therapeutic target against GBM.

PS02.038: SAFETY AND EFFICACY OF REPETITIVE PHOTODYNAMIC THERAPY FOR RESIDUAL ESOPHAGEAL CANCER LESIONS AFTER INITIAL PHOTODYNAMIC THERAPY

2018 ◽  
Vol 31 (Supplement_1) ◽  
pp. 130-131
Author(s):  
Masashi Tamaoki ◽  
Yusuke Amanuma ◽  
Takahiro Horimatsu ◽  
Shinya Ohashi ◽  
Manabu Muto
Keyword(s):  
Esophageal Cancer ◽  
Photodynamic Therapy ◽  
Conflicts Of Interest ◽  
Complete Response ◽  
Best Supportive Care ◽  
Local Failure ◽  
University Hospital ◽  
Safety And Efficacy ◽  
Lesion Depth ◽  
Talaporfin Sodium

Abstract Background Photodynamic therapy (PDT) is an effective salvage treatment for local failure after chemoradiotherapy in patients with esophageal cancers. However, the treatment strategy for local failure after initial PDT has not been established, and the safety and efficacy of repetitive PDT for such lesions are also unknown. Methods We retrospectively investigated 33 esophageal cancer patients who received initial salvage PDT at Kyoto University Hospital between May 2012 and November 2017. Additionally, we examined the treatment outcomes of those patients who received repetitive PDT. Results Twenty-one patients (64%) achieved local complete response (CR) by initial PDT, and local recurrence did not occur in those patients. Eleven patients (33%) had residual lesions after initial PDT. Among these, 7 patients were treated with repetitive PDT, 2 patients selected best supportive care, 1 patient was treated with surgery, and 1 patient was treated with chemotherapy. Five of the 7 patients who received repetitive PDT were treated with talaporfin sodium, and 2 patients were treated with porfimer sodium. The median age of the patients who received repetitive PDT was 70 years old, and all patients were men. Regarding histology, 6 patients were squamous cell carcinoma and 1 patient was adenocarcinoma. The median period from initial PDT to repetitive PDT was 3 months (range 1–4). Lesion depth before initial PDT was T1 in 3 patients and T2 in 4 patients. Lesion depth before repetitive PDT was T1 in 5 patients, and T2 in 2 patients. Local CR rate in 7 patients treated with repetitive PDT was 42.9% (3/7). Additionally, local CR rate in T1 cases was 60% and 0% in T2 cases. Adverse events of grade 3 or higher were not observed in any patient. Conclusion Repetitive salvage PDT was considered to be an effective and safe treatment option in residual T1 lesions after initial PDT for local failure of esophageal cancer treated with chemoradiotherapy. Disclosure All authors have declared no conflicts of interest.

Sign in / Sign up

Export Citation Format

Share Document